De Novo Pharmaceuticals

De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create new, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can rapidly transform information from structural genomics and medicinal chemistry into novel chemical designs, thereby maximizing the value of pharmaceutical partners' research portfolios. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals, and NV Organon.